<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01613014</url>
  </required_header>
  <id_info>
    <org_study_id>NCIG-004</org_study_id>
    <nct_id>NCT01613014</nct_id>
  </id_info>
  <brief_title>ABT-436 for Alcohol Dependence</brief_title>
  <official_title>A Phase 2, Double-Blind, Randomized, Placebo Controlled Trial to Assess the Efficacy of ABT-436 for Alcohol Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary efficacy endpoint examines the hypothesis that ABT-436 will decrease the weekly
      percentage of heavy drinking days during Study Weeks 2 through 12 (Days 8-84) as compared to
      placebo. A &quot;heavy drinking day&quot; is 4 or more drinks per drinking day for women and 5 or more
      drinks per drinking day for men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adrenocorticotropic hormone (ACTH) release from the pituitary gland via V1B stimulation is
      central to the hypothalamus-pituitary-adrenal (HPA) axis stress response (Carrasco &amp; Van de
      Kar-2003, Herman &amp; Cullinan-1997, Sapolsky et al-2000; Tsigos &amp; Chrousos-2002). Chronic
      dysregulation of the HPA axis is common in major depressive disorder, anxiety disorders, and
      substance abuse disorders characterized by elevated AVP, increased responsiveness to AVP, as
      well as either increased or decreased overall HPA axis activity or responsiveness (Dinan &amp;
      Scott-2005). HPA axis normalization via pituitary V1B antagonism is a mechanism for potential
      ABT-436 efficacy in these disorders (Schüle et al-2009). Limbic V1B antagonism in the brain
      may also contribute to efficacy (Roper et al-2011).

      Alcohol dependence, or alcoholism, is characterized by a chronic relapsing course, in which
      alcohol-associated cues and stress are known relapse triggers (Brownell et al-1986, Heilig &amp;
      Egli-2006, Sinha &amp; Li-2007). Recent research suggests that neural systems mediating
      behavioral stress responses may offer useful targets for pharmacotherapy of alcoholism. In
      animal models, excessive alcohol consumption that results from a history of alcohol
      dependence is accompanied by increased behavioral sensitivity to stress (Heilig &amp; Koob-2007).
      Preclinical studies have shown that V1B antagonists can attenuate reinstatement of heroin and
      alcohol self-administration, and block dependence-induced exaggeration of alcohol intake, in
      rats. V1B antagonists have also been shown to block stress-induced reinstatement of drug and
      alcohol seeking in ethanol dependent rats (Zhou-2011). For these reasons the NIAAA Clinical
      Investigations Group (NCIG) proposes to test ABT-436 in a Phase 2, proof of concept trial for
      the treatment of alcohol dependence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weekly Percentage of Heaving Drinking Days</measure>
    <time_frame>Weeks 2-12</time_frame>
    <description>The primary objective of this study is to assess the efficacy of ABT-436 to reduce the weekly percentage of heavy drinking days (reduction in drinking) in subjects with alcohol dependence confirmed by DSM-IV-TR criteria. A &quot;heavy drinking day&quot; is 4 or more drinks per drinking day for women and 5 or more drinks per drinking day for men.
The outcome measure was averaged across weeks 2-12.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Alcohol Dependence</condition>
  <condition>Alcohol Abuse</condition>
  <condition>Alcohol Use Disorders</condition>
  <condition>Alcoholism</condition>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched Placebo sugar pill - target dose 2 pills BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-436</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ABT-436 Target dose of 400 mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-436</intervention_name>
    <description>Target dose - 400mg BID</description>
    <arm_group_label>ABT-436</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matched Placebo - Sugar Pill</intervention_name>
    <description>Target Dose - 2 pills BID</description>
    <arm_group_label>Sugar Pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be at least 21 years of age and no more than 65 years of age.

          -  Have a current (past 12 months) DSM-IV-TR diagnosis of alcohol dependence.

          -  Be seeking treatment for alcohol dependence and desire a reduction or cessation of
             drinking.

        Exclusion Criteria:

          -  current (past 12 months) abuse or dependence on any psychoactive substance other than
             alcohol, caffeine and nicotine, including sedatives and hypnotics, as defined by
             DSM-IV-TR criteria.

          -  positive urine toxicology screen performed during screening or baseline.

          -  been hospitalized for alcohol intoxication delirium, alcohol withdrawal delirium,
             alcohol-induced persisting dementia or amnestic disorder, or have had an alcohol
             withdrawal seizure, alcohol-induced psychotic disorder with a primary diagnosis of
             alcohol dependence or a history of any seizure disorder.

          -  Have any of the following, based on DSM-IV-TR criteria as assessed using the MINI:

               1. Current, past, or lifetime diagnosis of psychotic disorders (note schizophrenia
                  is diagnosed under the psychotic disorder module of the MINI)

               2. Current or past diagnosis of bipolar disorder,

               3. Current or past year major depressive episode,

               4. Current (past 3 months) eating disorder (anorexia or bulimia), or

               5. Current (within past year) diagnosis of panic disorder with or without
                  agoraphobia,

               6. Anti-social personality disorder.

          -  Have any underlying medical condition that could exacerbate during trial participation
             causing hospitalization, surgery, and/or the need to use exclusionary medications to
             treat condition.

          -  Be pregnant or breast-feeding or have plans to become pregnant at any time during the
             study.

          -  Have a clinically significant abnormal laboratory value;

          -  Hemoglobin A1c value &gt; 7%.

          -  Have a clinically significant ECG as determined by the investigator or abnormal ECG
             heart rate (&lt;45 or &gt; 100 bpm or QTc interval corrected for heart rate using the
             Fridericia formula (QTcF) &gt; 450 msec.

          -  Have HIV or Hepatitis A, B or C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raye Litten, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Quincy</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2012</study_first_submitted>
  <study_first_submitted_qc>June 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2012</study_first_posted>
  <results_first_submitted>September 29, 2016</results_first_submitted>
  <results_first_submitted_qc>February 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 4, 2017</results_first_posted>
  <last_update_submitted>February 15, 2017</last_update_submitted>
  <last_update_submitted_qc>February 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcohol</keyword>
  <keyword>Alcohol Dependence</keyword>
  <keyword>Alcohol Abuse</keyword>
  <keyword>Alcohol Use Disorders</keyword>
  <keyword>Alcoholism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sugar Pill</title>
          <description>Matched Placebo sugar pill - target dose 2 pills BID
Matched Placebo - Sugar Pill: Target Dose - 2 pills BID</description>
        </group>
        <group group_id="P2">
          <title>ABT-436</title>
          <description>ABT-436 Target dose of 400 mg BID
ABT-436: Target dose - 400mg BID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>144 represents the modified intention to treat population (mITT) - took at least one dose of medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Sugar Pill</title>
          <description>Matched Placebo sugar pill - target dose 2 pills BID
Matched Placebo - Sugar Pill: Target Dose - 2 pills BID</description>
        </group>
        <group group_id="B2">
          <title>ABT-436</title>
          <description>ABT-436 Target dose of 400 mg BID
ABT-436: Target dose - 400mg BID</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
            <count group_id="B2" value="73"/>
            <count group_id="B3" value="144"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.5" spread="11.6"/>
                    <measurement group_id="B2" value="45.8" spread="10.2"/>
                    <measurement group_id="B3" value="45.7" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Weekly Percentage of Heaving Drinking Days</title>
        <description>The primary objective of this study is to assess the efficacy of ABT-436 to reduce the weekly percentage of heavy drinking days (reduction in drinking) in subjects with alcohol dependence confirmed by DSM-IV-TR criteria. A “heavy drinking day” is 4 or more drinks per drinking day for women and 5 or more drinks per drinking day for men.
The outcome measure was averaged across weeks 2-12.</description>
        <time_frame>Weeks 2-12</time_frame>
        <population>Models are based on a mITT population that included subjects who received at least one dose of medication (N=144; ABT-436=73, placebo=71). One additional placebo subject had no drinking data during the maintenance period, and one ABT-436 subject was missing data on a baseline covariate, resulting in an analyzable N=142 (ABT-436=72, placebo=70).</population>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill</title>
            <description>Matched Placebo sugar pill - target dose 2 pills BID
Matched Placebo - Sugar Pill: Target Dose - 2 pills BID</description>
          </group>
          <group group_id="O2">
            <title>ABT-436</title>
            <description>ABT-436 Target dose of 400 mg BID
ABT-436: Target dose - 400mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Percentage of Heaving Drinking Days</title>
          <description>The primary objective of this study is to assess the efficacy of ABT-436 to reduce the weekly percentage of heavy drinking days (reduction in drinking) in subjects with alcohol dependence confirmed by DSM-IV-TR criteria. A “heavy drinking day” is 4 or more drinks per drinking day for women and 5 or more drinks per drinking day for men.
The outcome measure was averaged across weeks 2-12.</description>
          <population>Models are based on a mITT population that included subjects who received at least one dose of medication (N=144; ABT-436=73, placebo=71). One additional placebo subject had no drinking data during the maintenance period, and one ABT-436 subject was missing data on a baseline covariate, resulting in an analyzable N=142 (ABT-436=72, placebo=70).</population>
          <units>weekly percentage of heavy drinking days</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6" lower_limit="29.2" upper_limit="45.9"/>
                    <measurement group_id="O2" value="31.3" lower_limit="23.4" upper_limit="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The sample size for the adverse event table is 144 which is the mITT population - subjects who took at least one dose of medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sugar Pill</title>
          <description>Matched Placebo sugar pill - target dose 2 pills BID
Matched Placebo - Sugar Pill: Target Dose - 2 pills BID</description>
        </group>
        <group group_id="E2">
          <title>ABT-436</title>
          <description>ABT-436 Target dose of 400 mg BID
ABT-436: Target dose - 400mg BID</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Peptic Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>From a bee sting</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood Creatine Phosphokinase</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophil Count Increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Eosinophil Count increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Red blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Megan Ryan, Clinical Program Director</name_or_title>
      <organization>NIAAA</organization>
      <phone>3014434225</phone>
      <email>mryan1@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

